Botanical medicines for the treatment of cancer: Rationale, overview of current data, and methodological considerations for phase I and II trials
Botanical medicines for the treatment of cancer: Rationale, overview of current data, and methodological considerations for phase I and II trials
复制标题
DOI：
10.1081/cnv-120005926
复制
发表时间：
2002-01-01
影响因子：
2.4
通讯作者：
Vickers, A
中科院分区：
文献类型：
--
作者：
Vickers, A
公众对植物药或“草药”的热情似乎越来越高，特别是在癌症患者中。这一点最近开始得到越来越多的科学关注。虽然已知植物提取物具有抗癌活性，但标准方法是分离、合成和施用被认为负责这种效果的单一化合物。然而，植物中的不同组分可能具有协同活性。还有一些证据表明，植物提取物中存在多种化合物可以缓冲单一成分的毒性作用。虽然许多受患者欢迎的植物药可能没有益处（例如槲寄生，Pau D 'arco），但一些植物药在III期（Sho-saiko-to，PSK）或II期（PC-SPES）试验中显示出了希望。植物药材的质量控制带来了重大挑战：遗传、土壤、温度、湿度和收获时间的微小差异可能导致重要成分浓度的显著差异。I期和H期方法也存在问题：植物性药物毒性低，不太可能导致肿瘤快速消退。目前对植物药的管制很少。
There appears to be exceptional and growing public enthusiasm for botanical, or "herbal", medicines, especially amongst cancer patients. This has recently begun to be matched by increasing scientific attention. Whilst it is known that plant extracts are active against cancer, the standard approach has been to isolate, synthesize and administer the single chemical compound thought responsible for this effect. However, different components in a botanical may have synergistic activities. There is also some evidence that the presence of multiple compounds in a botanical extract can buffer the toxic effects of a single constituent. Though many of the botanicals popular among patients are probably not of benefit (e.g. Mistletoe, Pau D'arco), several botanicals have shown promise in Phase III (Sho-saiko-to, PSK) or Phase II (PC-SPES) trial. Quality control of botanicals poses significant challenges: small differences in genetics, soil, temperature, moisture and time of harvesting can lead to significant differences in the concentration of important constituents. Phase I and H methodology is also problematic: botanicals have low toxicity and are unlikely to cause rapid tumor regression. There is currently minimal regulation of botanical medicines.